Factors Associated With Persistent Efficacy of Abrocitinib Without Flare: A Multivariable Analysis of the JADE-REGIMEN Study

Simple item page
dc.coverageDOI: 10.25251/skin.8.supp.378
dc.creatorThyssen, Jacob P.
dc.creatorSilverberg, Jonathan I.
dc.creatorBlauvelt, Andrew
dc.creatorCriado, Paulo R.
dc.creatorGubelin, Walter
dc.creatorRuano, Juan
dc.creatorRojo, Ricardo
dc.creatorTerry, Ketti
dc.creatorValdez, Hernan
dc.creatorBiswas, Pinaki
dc.creatorFeeney, Claire
dc.date2024
dc.date.accessioned2025-11-18T19:52:46Z
dc.date.available2025-11-18T19:52:46Z
dc.description<p>BACKGROUND • Atopic dermatitis (AD) is a chronic skin disease that presents with eczematous lesions and intense pruritus1,2 • Patients with moderate-to-severe AD have a chronic, relapsing course that warrants systemic maintenance therapy in order to control disease and reduce the number and severity of flares1 • An important consideration when using long-term therapy is to use the lowest possible drug dose to reduce the risk for adverse events1 • JADE REGIMEN (NCT03627767) evaluated the efficacy and safety of continuous abrocitinib, dose reduction, or withdrawal of abrocitinib after induction of response with once-daily oral abrocitinib 200 mg in patients with moderate-to-severe AD3 • Predicting risk for disease flare can inform selection of appropriate maintenance therapy for patients with moderate-to-severe AD who achieve skin clearance after 12 weeks of induction monotherapy with abrocitinib 200 mg OBJECTIVES • To evaluate patient factors associated with a higher probability of persistent clinical response with different abrocitinib doses, with no protocol-defined flare, during a 40-week maintenance period • To create a nomogram, based on the patient factors identified above, to predict the probability of flare for individual patients with AD.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/2a0692a6-476f-4346-af5f-8b076fae22cc
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/57897
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.8 (2024) nr.2 p.S378
dc.titleFactors Associated With Persistent Efficacy of Abrocitinib Without Flare: A Multivariable Analysis of the JADE-REGIMEN Studyeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE